In the face of childhood neurodevelopmental disorders, how can we get out of the therapeutic "dead end"? The answer could well be found in the genes of the proteasome – an intracellular mechanism that is responsible for removing defective proteins from the cell.
Correct immune system function depends on the continuous supply of white blood cells derived from stem cells that reside in the bone marrow. These are known as blood stem cells or hematopoietic stem cells. Researchers from Inserm, CNRS and Université d’Aix-Marseille at the Center of Immunology Marseille-Luminy have now discovered a new role played by these cells in immune response.
One year after its large-scale poster campaign in France’s railway stations and Paris subway, Inserm uses its slogan On gagne tous les jours à s’intéresser à la santé [We always benefit from focusing on health] in a 30-second TV commercial broadcast from June 7 to July 30.
CAR T cell therapy is an immunotherapy that is effective in treating blood cancer. By closely investigating some of the immune cells generated during this therapy, known as CD4 T cells, scientists from the Institut Pasteur and Inserm, in collaboration with clinicians from the Paris Public Hospital Network (AP-HP), discovered that these cells are capable of remotely neutralizing tumor cells by producing interferon gamma (IFN-γ).
In order to understand its genetic causes and biological mechanisms, a new international study led by Inserm Research Director Nabila Bouatia-Naji at the Paris-Cardiovascular Research Center - PARCC (Inserm/Université Paris Cité) was set up. Its findings show the genetic causes that define the risk of SCAD to be very numerous and distributed across the entire patient genome.
Researchers from Inserm, Université Paris-Saclay and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ) with the Gustave Roussy Institute studied the impact of physical activity on the development of PD in nearly 100,000 women from the French cohort E3N followed up over 29 years.
The health outcomes of the nuclear tests performed in French Polynesia in the 1970s have been the subject of epidemiological studies at Inserm for several years. In a new publication, the scientists confirm these findings and conduct a risk prediction analysis showing that these nuclear tests could be responsible for 2.3% of the thyroid cancer cases.